Allogeneic stem cell transplantation (SCT) results in alloimmune attack of donor lymphocytes on recipient tissue, manifesting clinically as graft-versus-host disease (GVHD). The skin, liver, gut and lungs are the most common targets, with external manifestations such as coarsening of skin, erythema, alopleica and vitiligo, which may cause disfigurement and functional impairment. The most common ophthalmic GHVD complication after SCT is tear deficiency and 'Sjogren-like syndrome', which can lead to punctate keratitis. 1 Steroid treatment of GVHD can also cause secondary subcapsular cataracts. On the other hand, ptosis is an uncommon vision threatening complaint after SCT. We report a collection of severe post SCT ptosis in adult Chinese patients and investigate the possible presence of an alloimmune cause of levator muscle weakness due to neuromuscular transmission defect.
Material and methods
From 1993 to 2001, 346 consecutive adult patients underwent myeloablative allogeneic SCT and achieved engraftment over 3 months. Their median age was 34 (range, and included 202 males and 144 females. Molecular HLA typing was performed for the HLA A, B and DR loci. The conditioning protocols were chosen according to the disease and degree of HLA matching. Cyclosporin A (CsA) and methotrexate were used for GVHD prophylaxis. Significant acute GVHD (aGVHD) and chronic GVHD (cGVHD) occurred in 34% and 26% of patients, respectively. Regular ophthalmology follow-up for dry eyes and other complications was recorded in 264 cases (73%), and all patients were on artificial tears supplements. The ocular assessment included indirect fundoscopy, slit-lamp examination, Schirmer's test for ocular sicca, applanation tonometry and best-corrected visual acuity (BCVA) assessment by Snellen chart. Six patients were referred for neuroophthalmological assessment for severe bilateral ptosis, and were investigated along the lines of myasthenia gravis (MG). Anti-acetylcholine receptor (Ach Ab) and antistriated muscle antibodies (St Ab) were measured by standard ELISA technique. Screening for Ach Ab and anti St Ab was also performed in a consenting matched control group of 20 among 85 remaining post SCT cases with cGVHD but without ptosis (male : female ratio 1 : 3, median age 44, range 22-55; median 29 months interval from SCT, range 10-86). Tensilon test and standard and single fibre electromyogram (SF-EMG) were performed according to standard protocols on the subjects but not the controls. Briefly, five single muscle fibre pairs were sampled at the frontalis muscle, a standard procedure used for the specific diagnosis of ocular MG. 2, 3 Electromyographic readings were compared with readings standardized for age and anatomical site in local Chinese population. Jittering, defined as increased mean interpotential interval (MIPI), mean consecutive difference (MCD), mean sorting difference (MSD) and impulse blocking, in two or more fibre pairs was taken as positive for myasthenia. 4 The less commonly used (and more invasive) direct needle testing on the levator palpebrae muscle was not performed locally and there is no Hong Kong Chinese data on myasthenia and controls. Statistical significance was calculated by Fisher's exact test and student's t-test as appropriate (SPSS 10.0, Chicago, IL, USA). Relative risks were calculated using a proportion hazards model. Results were expressed in twotailed significance levels and 95% confidence intervals.
Results

Clinical features
The severity of ptosis was quantified by the maximum distance between the eyelids (interpalpebral distance IPD, normal Chinese 47 mm) and the distance between the upper eyelid and point of reflection of the light reflex with a torch shone straight ahead (marginal reflex distance MRD, normal Chinese 42 mm). The patients included five females and one male with a median age of 43 (range 35-55) (Table 1) , with a mean MRD of 0.78 mm and IPD of 4.8 mm (Figure 1a ). The initial diagnosis included chronic myeloid leukemia (CML, n ¼ 3), acute myeloid leukemia (AML, n ¼ 2) and myeloma (n ¼ 1), all without total body irradiation conditioning. The median time from SCT to the complaint of ptosis was at 52 months (range 15-117), and two patients volunteered significant convincing diurnal variations of fatigability. None of the patients experienced diplopia, limb weakness or dyspnea. All six patients suffered from aGVHD and cGVHD, and two were maintained on long-term azathioprine. On univariate analysis, both aGVHD (P ¼ 0.001, RR: 3.0, 95% CI: 2.6-3.5) and cGVHD (Po0.001, RR: 4.0, 95% CI: 3.4-4.9) were significantly associated with post SCT ptosis. However, female sex (P ¼ 0.086, RR: 7.23, 95% CI: 0.83-62.6) showed only a trend towards increased risk of bilateral ptosis, while donor sex, HLA typing and underlying diagnosis were not significant. All six patients suffered from dry eyes and the median Schirmer test result was 6.5 mm (range 3-12 mm, normal 415 mm), with ductal occlusion surgery done in case 4. This was not significantly different from the median Schirmer test results of all SCT cases with cGVHD (median 6.6, range 2-16 mm, P ¼ 0.92, t-test). Furthermore, there was no superficial punctate keratopathy in all six cases with ptosis. Levator muscle weakness was managed conservatively in two cases, while three patients did not respond to mestinon (40 mg 5 Â per day) or prednisolone (up to 40 mg). One patient (Case 6) underwent surgery with bilateral advancement of levator aponeurosis, with satisfactory results at 2-year follow-up. Muscle biopsy was not performed. Further sampling of fibres not performed due to patient discomfort and refusal.
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Laboratory investigations
Tensilon tests for all six cases were either negative or equivocal. Computerized tomogram scan did not show thymic hyperplasia, and all patients were euthyroid. The level of Ach Ab was raised in all cases, with a median titre of 0.74 IU (range 0.46-5.2, normal o0.43 IU/ml); while anti St Ab was detected in three cases. Among control cases, the median titre for Ach Ab was 0.28 IU, with 4/20 patients showing positive titres from 0.53 to 1.6 IU, respectively. This was significantly different from the ptosis cohort (P ¼ 0.01, Student's t-test). Anti St Ab was detected in 4/20 control cases, which was statistically not significantly different from the incidence in the ptosis cohort (P ¼ 0.29, Fisher's exact test). Electrophysiological studies were performed on all cases. Nerve conduction parameters were normal, except for moderate conductive defect in Case 2. Repetitive nerve stimulation studies performed over trapezius showed no significant decremental cMAP response at baseline and at post-exercise exhaustion. However, in 5/6 cases, SF-EMG sampling at frontalis muscle showed irregular recruitment effort. This consisted of significantly excessive jitter and block, suggesting neuromuscular conduction restricted to the frontalis muscle (Figure 1b and c) . Due to invasive nature of the test, SF-EMG was not performed on control GVHD subjects.
Discussion
With prolonged survival of patients after SCT, chronic problems affecting the quality of life begin to surface. Ptosis after SCT has never been explored, and it presents both diagnostic and therapeutic problems. Significant acquired bilateral blepharoptosis in young adults is uncommon. Causes such as blepharospasm, injury and contact lens use were excluded in our patients. The normal nerve conduction and EMG amplitudes also excluded neuropathy and myopathy. Other causes, for example, steroid myopathy or drug side effects or electrolyte disturbances, were also unlikely in view of negative laboratory screening and localized defects. Although most post SCT patients suffered from dry eyes, the severity was not accentuated in the six cases and there was no evidence of keratitis to produce secondary ptosis. Hence, our study focused on the possibility of the existence of neuromuscular block or evidence of post SCT ocular MG.
Myasthenia as a cause of muscle weakness after allogeneic SCT was first reported in 1983 and a donor lymphocyte mediated pathogenesis was documented. 5 Known associations include significant GVHD, 6 aplastic anemia, female gender, sex mismatched SCT and cessation of immunosuppressants. 7, 8 Unlike de novo MG, there was no association with thymoma or thyroiditis. 8 Reported HLA associations for post SCT MG included HLA B7, Cw1, Cw7 and DR2 in different populations. 7, 8 The median latency was 42 months. 9 The response to mestinon is poor and immunosuppression (especially steroids) remained the mainstay of treatment. Our collection of cases is unique in that weakness was exquisitely localized to the ocular muscles. It is uncertain whether this hitherto unreported entity is peculiar to ethnic Chinese. The clinical spectrum of de novo MG in Chinese is similar to Caucasians (with 2:1 female predominance, median age of 36 years and 30% association with thymoma and thyroid disease), 10 except for a high incidence of ocular MG (1/3 of cases). It usually runs a benign localized course, and unlike generalized MG, it is not associated with HLA B46 or DR9.
11
Our collection highlighted the diagnostic and therapeutic difficulties in tackling post SCT ptosis. The lack of unequivocal fatiguability and tensilon response makes it difficult to classify them as a variant of ocular MG. On the other hand, the immunological and electrophysiological results are reminiscent that of clinical ocular MG. There are, however, several other possible causes of diagnostic uncertainty. Firstly, low titres of anti Ach and St Ab are common after allogeneic SCT and most patients do not develop ocular or muscle weakness. 12, 13 Furthermore, in de novo ocular MG, only 65% of patients carry Ach-Ab, and in lower titres compared with generalized MG.
14 Secondly, both de novo ocular MG and post SCT generalized MG tend to respond poorly to cholinergic stimulation, and negative tensilon test and fatiguability does not exclude the diagnosis. 8, 14 Nevertheless, our data suggested that among cases with GVHD, patients with positive antibodies at higher titres are at increased risk to develop ptosis, probably due to localized neuromuscular conduction block. For most cases, however, the chronic nature of the ptosis, and the poor response to mestinon and steroids treatment support a conservative diagnostic and therapeutic approach to the problem. The satisfactory results of levator muscle surgery suggested that this, or other forms of surgery, for example frontalis slings and tarsomyectomy, are possible options. As in de novo ocular MG, the requisites for surgery should include objective interpalpebral eyelid fissure height 15 and subjective symptoms (visual field and cosmesis), 16 and stable disease (in this case, in terms of both leukemia and GVHD as well as ptosis). 17 In conclusion, we have shown that post SCT ptosis may present as a significant ophthalmological problem for some leukemia survivors with cGVHD. Immunological and electrophysiological data hinted an association with localized neuromuscular transmission defect analogous to that in ocular MG. Although progression to generalized MG did not occur, medical treatment is ineffective and most case continued to deteriorate. For severe and stable cases, corrective surgery is indicated.
